Loading...
NPI 1740733708 · Chicago, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Tempus Ai, Inc. is a clinical medical laboratory provider located in Chicago, Illinois. This profile covers 15 Medicare and 50 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Tempus Ai, Inc. |
| Address | 600 W Chicago Ave Ste 510 |
| City | Chicago |
| State | IL |
| ZIP | 60654 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 26, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $132M |
| Medicaid | $22M |
TEMPUS AI, INC. is primarily a high-volume molecular and genomic testing laboratory focused on large-panel oncology diagnostics: Medicare billing is dominated by genomic sequence analysis panels 81455 and 81456 (together representing $86.2M and $42M in Medicare revenue respectively), and the CPT mix also includes high volumes of pathology ancillary codes such as 88360 and 88341. The prominence of 81455/81456, both with very high avg paid/claim on Medicare ($2857 and $2856), indicates the operation centers on comprehensive DNA/RNA cancer panels and associated anatomic pathology support services.
Revenue concentration is extreme on Medicare, where the precomputed top-3 Medicare codes account for 98.1% of this provider's total Medicare revenue, meaning the business is highly dependent on a very small set of molecular panel codes for Medicare cash flow. This concentration suggests that reimbursement policy or clinical guideline changes affecting those specific codes could materially affect overall Medicare revenue.
On Medicaid the top 3 codes are also concentrated but less so: the precomputed top-3 Medicaid codes account for 68.4% of the provider's total Medicaid revenue, with 81455 ($9M), U0004 ($3.3M), and 81456 ($2.4M) together forming the largest portion of Medicaid receipts. The Medicaid mix shows a combination of oncology-focused panels alongside substantial SARS-CoV-2 testing activity, indicating dual operational capacity for both specialty molecular oncology services and high-throughput infectious disease testing.
Payer mix is heavily Medicare-weighted: lifetime Medicare revenue is $132M compared with lifetime Medicaid revenue of $22M, so Medicare is the dominant payer by scale for this NPI. That imbalance underscores strategic exposure to national Medicare payment trends while Medicaid contributes a meaningful but much smaller share of volume, including a nontrivial share from public-health testing codes.
TEMPUS AI demonstrates national leadership on its core genomic codes for Medicare: 81455 ranks #1 of 36 providers nationally at the 100th percentile and is labeled an "extreme outlier," and 81456 ranks #1 of 6 providers nationally at the 100th percentile and is described as "notably above typical national volume." These rankings imply the provider is a leading, high-volume national performer on large-panel genomic oncology testing.
Several pathology support codes also show statistically extreme volumes on Medicare and in-state Medicaid comparisons: 88360 ranks #2 of 5330 providers nationally (100th percentile; "extreme outlier") on Medicare, and 88341 and 88342 rank at the 100th percentile in-state on Medicaid with very large claim counts. Those patterns indicate integrated anatomic pathology services that scale to support the provider's molecular testing throughput, not just stand-alone molecular billing.
Many Medicaid line items (including 81455, 81456, 81162, 81292, 81317 and others) show rank #1 of 1 in-state with a 0th percentile flag, reflecting a lack of comparable in-state peers in the dataset for those specialized molecular assays. This suggests that in Illinois the provider may be one of the few in-state sources billing Medicaid for many high-complexity genomic tests, which has implications for state-level contracting and access.
The NPI has been enumerated since 2016-07-26 (~10 years ago), indicating about a decade of claims activity under this enrollment. Combined with the coding and ranking profile, tenure supports the interpretation that TEMPUS AI has built sustained high-volume molecular and pathology operations nationally (for Medicare) and regionally (for Medicaid) over that period.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
15 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81455 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to… | 30,180 | $2,860 | $86.2M |
| 81456 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for RNA alterations in 51 or more genes known to relate to solid… | 14,720 | $2,860 | $42M |
| 88360 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist, evaluates the… | 12,710 | $90 | $1.2M |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 15,760 | $70 | $1.1M |
| 88381 | A clinician, typically a pathologist, performs a manual microdissection of a patient’s specimen, such as a biopsy or tissue preserved from a previous case. | 3,850 | $160 | $627.9K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 5,330 | $80 | $431.5K |
| 88387 | The analyst performs all the technical steps to examine a tissue specimen using normal sight, dissect out the part of the specimen needed for testing, and then prepare the tissue for nonmicroscopic… | 6,910 | $30 | $186.6K |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 50 | $1,750 | $78.8K |
| 81301 | The lab analyst performs the technical lab test to detect the presence of microsatellite instability, also known as MSI, in tumor cells from tissue specimens such as colon cancer. | 80 | $340 | $26.7K |
| 81235 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for epidermal growth factor receptor, also known as EGFR. | 50 | $320 | $16.2K |
Showing 1–10 of 15
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 15 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
15 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81455 | 1 | 10 | 15,140 | $2,860 | $43.3M |
| 81456 | 1 | 10 | 14,720 | $2,860 | $42M |
| 81162 | 2 | 10 | 240 | $1,780 | $417.7K |
| 88381 | 1 | 10 | 20 | $150 | $45.8K |
| 88387 | 1 | 10 | 100 | $30 | $39.4K |
| 81301 | 1 | 10 | 80 | $340 | $26.6K |
| 81235 | 1 | 10 | 50 | $320 | $16.2K |
| 81276 | 1 | 10 | 80 | $190 | $14.4K |
| 88341 | 1 | 450 | 210 | $30 | $11.9K |
| 88342 | 2 | 490 | 120 | $40 | $9K |
Showing 1–10 of 15
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
50 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81455 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to… | 14,870 | $610 | $9M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 50,150 | $70 | $3.3M |
| 81456 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for RNA alterations in 51 or more genes known to relate to solid… | 5,470 | $430 | $2.4M |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 1,770 | $410 | $714.8K |
| 81292 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutL homolog 1, or MLH1 gene, also known as the colon cancer or nonpolyposis type 2 gene. | 6,650 | $90 | $624.6K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 6,520 | $100 | $619.7K |
| 88360 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist, evaluates the… | 14,650 | $30 | $439.4K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 6,590 | $70 | $434.7K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 17,470 | $20 | $384.4K |
| 81301 | The lab analyst performs the technical lab test to detect the presence of microsatellite instability, also known as MSI, in tumor cells from tissue specimens such as colon cancer. | 6,700 | $60 | $368.5K |
Showing 1–10 of 50
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
50 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81455 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to… | 1 | 10 | 14,870 | $610 | $9M |
| 81456 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for RNA alterations in 51 or more genes known to relate to solid… | 1 | 10 | 5,470 | $430 | $2.4M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2 | 50 | 710 | $70 | $1.2M |
| 81292 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutL homolog 1, or MLH1 gene, also known as the colon cancer or nonpolyposis type 2 gene. | 1 | 10 | 6,650 | $90 | $624.2K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 1 | 10 | 6,520 | $100 | $621.7K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 1 | 10 | 6,590 | $70 | $431.5K |
| 81301 | The lab analyst performs the technical lab test to detect the presence of microsatellite instability, also known as MSI, in tumor cells from tissue specimens such as colon cancer. | 1 | 10 | 6,700 | $50 | $368.5K |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 1 | 10 | 890 | $400 | $360.4K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 1 | 10 | 3,730 | $90 | $339.4K |
| 81194 | The lab analyst performs the technical lab test using a specimen such as formalin–fixed paraffin embedded tissue (FFPE) to analyze NTRK (neurotrophic receptor tyrosine kinase) translocations for the… | 1 | 10 | 3,110 | $90 | $294.3K |
Showing 1–10 of 50
Other providers in the same ZIP code as Tempus Ai, Inc., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Amitoj Mehta | IL | General Practice Dentistry | $0 | $5.2M |
| Family Guidance Centers, Inc. | IL | Methadone Clinic | $105.6K | $3.4M |
| Ishmeet Singh | IL | Interventional Pain Medicine Physician | $2.2M | $611.6K |
| Mehbub Kapadia | IL | Internal Medicine Physician | $471.2K | $514.6K |
| Salvador Yunez | IL | Phlebology Physician | $544.1K | $0 |
| Prashant Chawla | IL | Neuroradiology Physician | $258.5K | $0 |
| Argiro Zofakis | IL | Internal Medicine Physician | $241.8K | $5.1K |
| Center For Addictive Problems, Inc | IL | Methadone Clinic | $221.7K | $14.1K |
| Christian Bonzheim | IL | Physician Assistant | $27.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.